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AEROSOLIZED AND INTRAVENOUS RIBAVIRIN IN VIRAL RESPIRATORY
INFECTIONS IN IMMUNOCOMPROMISED PEDIATRIC PATIENTS
Therrien, R., Crisinel, P.-A., Gharbi, M., Raimbault, M., Buteau, C.
CHU Ste-Justine, Montreal, QC, Canada
Objective:To describe the use of ribavirin in immunocompromised
patients in a pediatric tertiary care center.
Patients and Methods: All immunocompromised patients who re-
ceived aerosolized or intravenous ribavirin for the treatment of a re-
spiratory viral infection from February 2001 through September
2007 were retrospectively included.
Results:Twenty-three patients were included, 11 boys and 12 girls.
The median age was 3.3 years (5.5 months to 17 years). Eighteen
patients (78%)were recipients of haematopoietic stem cell transplant
(HSCT). Two were treated for ALL, one had received a liver trans-
plant, one was HIV positive and one had a Fanconi syndrome.
Eleven patients (48%) received aerosolized ribavirin, 6 (26%) re-
ceived it intravenously and 6 (26%) received it by both routes but
not concomitantly. Mean ribavirin treatment was 30 days (4-105
days). Aerosolized ribavirin dose was 2 g over 2 hours every 8 hours
in 14/17 patients. For intravenous ribavirin, a median loading dose of
30 mg/kg (range 13-38) was used followed by maintenance doses
ranging from 4 to 23 mg/kg every 6 hours. Patients were treated
with ribavirin for the following infections: 11 respiratory syncytial vi-
rus, 14 parainfluenza virus (PIV) (9 PIV-3, 3 PIV-1, 2 PIV-2), 5 ad-
enovirus and one influenza A. Nine cases of viral co-infections were
observed. The mortality rate was 48% (11/23); 4 deaths (17%) were
related to the viral infection, 6 were due to pre-existent disease and
the cause of death remains uncertain in one case. The 4 patients
that died of viral infections were all HSCT patients. Fourteen pa-
tients (61%) received mechanical ventilation with a mean duration
of 19 days (2-55 days).
Conclusion:This is one of the largest series describing the use of in-
travenous ribavirin in immunocompromised pediatric patients with
respiratory virus infections. We found a 17% mortality rate linked
with the viral infection, which is comparable thanwhat has been pub-
lished previously.Table 1. Results of Cyclophosphamide plus Filgrastim Che-
momobilization in Multiple Myeloma Patients Following Le-
nalidomide Treatment
Group A
(LEN-treated pts)
Group B (non-LEN-
treated pts) p value
Total CD34+ cells  106/kg,
median (range)
7.43 (0-11.81) 9.15 (2.15-69.57) 0.159*
Total CD34+ cells  106/kg
after 2 leukapheresis, median
3.34 8.13 0.06*
Number of leukapheresis
sessions, median (range)
3 (1-5) 2 (1-5) 0.42*
Pts failing to collect minimum
CD34+ cells (%)
2 (17) 0 (0) 0.105**
*2-sided Mann-Whitney U test.
**Fisher’s exact test.546
COMPARATIVE COST-EFFECTIVENESS OF PLERIXAFOR PLUS GRANULO-
CYTE-COLONY STIMULATING FACTOR VERSUS CYCLOPHOSPHAMIDE
PLUS GRANULOCYTE-COLONY STIMULATING FACTOR FOR AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PATIENTS
WITH MULTIPLE MYELOMA
Campen, C.J.1,2, Yeager, A.M.2, Green, M.R.1,2, Armstrong, E.P.3
1University Medical Center, Tucson, AZ; 2Arizona Cancer Center, Tuc-
son, AZ; 3University of Arizona College of Pharmacy, Tucson, AZ
Introduction: Chemotherapy + G-CSF and plerixafor (PLX) + G-
CSF effectively mobilize CD34+ cells for autologous stem cell trans-
plantation (ASCT), but are both associated with varying degrees of
efficacy, cost, and toxicity. We performed a retrospective study to
evaluate the differences in cost, effectiveness, and toxicity of first-
line mobilization of autologous peripheral blood stem cells (PBSC)
with cyclophosphamide (CY; 1.5-4 gm/m2) + G-CSF (n5 48) versus
PLX + G-CSF (n 5 19) in pts with multiple myeloma (MM).
Methods: Between 5/2006 and 7/2010 67 consecutive patients un-
dergoing mobilization for ASCT were retrospectively analyzed.
Comparative statistical analysis using minimum ($ 2 x 106) and op-
timal ($ 6 x 106) CD34+ cell/kg was performed. A decision analytic
model was also created to estimate the mean costs and effectiveness
rates for the two regimens. This model incorporated the minimum
acceptable CD34+ cell dose for autologous PBSC transplant and ad-
verse events such as clinically significant anemia, thrombocytopenia,
and hospital admissions for neutropenic fever. Costs were from the
perspective of a managed care organization and based on published
data. A treatment success for the model was defined as a minimum
CD34+ cells/kg of $ 2 x 106. We conducted a Monte Carlo simula-
tion of 1,000 cases.
Results: The minimum number of cells for successful PBSC mobi-
lization occurred in 46 of 48 pts (96%) in the CY group and in 19 of
19 pts (100%) in the PLX group (p0.366). Of the two patients thatfailed chemomobilization, both successfully collected with PLX +
G-CSF. Optimal cell dose collection occurred in 41/48 (85%) and
15/19 (79%) patients treated with CY and PLX respectively
(p0.519). A median of 2 collections were required for CY + G-CSF
versus 1 with PLX + G-CSF (p0.128). Seven patients mobilized
with CY + G-CSF were admitted for neutropenic fever. (p0.079 ver-
sus PLX). The mean costs were $14,149 and $13,087 for PLX + G-
CSF and CY + G-CSF, respectively. Overlap was observed in the
95% confidence intervals for both cost and effectiveness between
the two regimens.
Conclusion: Cyclophosphamide + G-CSF is equally cost-effective as
PLX+G-CSFamongMMpatients undergoing stemcellmobilization.
Plerixafor + G-CSF may provide opportunities for improved autolo-
gous PBSC transplant efficiency. This analysis does not consider pa-
tient, clinic, and provider convenience as well as patient quality of life.547
CHEMOMOBILIZATIONWITH CYCLOPHOSPHAMIDE AND FILGRASTIM IN
MULTIPLE MYELOMA PATIENTS FOLLOWING LENALIDOMIDE TREAT-
MENT
Gerfen, A.D.1, Campen, C.J.2,3, Yeager, A.M.3, Green, M.R.2,3
1University of Arizona, Tucson, AZ; 2UniversityMedical Center, Tucson,
AZ; 3Arizona Cancer Center, Tucson, AZ
Background: No standard of care exists for treatment of multiple
myeloma (MM). Autologous stem cell transplant (ASCT) is the
current gold standard following induction therapy to improve over-
all survival. Lenalidomide (LEN) is used for treatment of MM
before ASCT, but antecedent exposure may impair autologous pe-
ripheral blood stem cell (PBSC) mobilization. Several strategies are
emerging to overcome LEN-induced impaired PBSC mobilization.
However, chemomobilization with cyclophosphamide (CTX) has
not been evaluated in this setting. CTX + filgrastim was investi-
gated to determine if LEN-associated mobilization impairment
can be abrogated.
Patients andMethods: 36 pts (group A 5 12 pts who received $ 2
cycles of LEN and group B 5 24 pts without LEN) from a single
center were analyzed retrospectively. Baseline characteristics were
matched (p . 0.05 for all variables). Three of 24 (13%) pts in
group B and 0 in group A received prior melphalan (p 5 0.09).
All pts received CTX (median group B, 1.5g/m2, range, 1.2-4; me-
dian group A, 3gm/m2; range, 1.5-4; (p 5 0.18)) and filgrastim
10mg/kg/day. Autologous PBSCs were collected by large volume
leukapheresis (3x blood volume). Mobilization failure was defined
as failure to collect at least 2x106/kg CD34+ cells. Primary out-
comes include total number of CD34+ cells collected and total
number of leukapheresis sessions. Secondary outcomes include fail-
ure to collect CD34+ cells and total CD34+ cells collected after
second leukapheresis.
Results (Table 1): Total median number of CD34+ cells collected
in group B 5 9.15x106/kg CD34+ cells (range, 2.15-69.57x106/kg
CD34+ cells) and group A 5 7.43x106/kg CD34+ cells (range, 0-
11.81x106/kg CD34+ cells) (p5 0.159).Median number of apheresis
sessions in group B 5 2 (range, 1-5) and group A 5 3 (range, 1-5)
(p 5 0.42). Two of 12 (17%) pts with antecedent LEN usage failedS349
S350 Poster Session IIto collect while no patient (0%) without previous LEN exposure
failed to collect, including 3 pts who received melphalan (p 5
0.105). Total number of CD34+ cells collected after 2 apheresis ses-
sions for group B 5 8.13x106/kg CD34+ cells and group A 5
3.34x106/kg CD34+ cells (p 5 0.06).
Conclusion: Chemomobilization with CTX + filgrastim yields ro-
bust PBSC collections irrespective of antecedent lenalidomide.
There was a trend towards lesser PBSC collection in LEN-treated
pts. Due to retrospective design and limited number of pts, further
research is needed to elucidate the effect of chemomobilization on
PBSC collection in LEN-treated pts.548
ADDITION OF RITUXIMAB TO EITHER BEAC OR BEAM IN THE PREPARA-
TIVE REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTSWITH RELAPSED B-CELL NON-HODGKIN LYMPHOMA DOES
NOT ADD A SURVIVAL BENEFIT: A SINGLE CENTER EXPERIENCE
Williams, C.B., Loknath-Kumar, A., Divine, C.L., Aljitawi, O.A.,
Abhyankar, S., McGuirk, J.P., Ganguly, S. University of Kansas Medical
Center, Kansas City, KS
High-dose chemotherapy with carmustine, etoposide, cytosine
arabinoside, and melphalan (BEAM) or cyclophosphamide
(BEAC) followed by autologous hematopoietic stem cell
transplantation (ASCT) represents a standard therapy for many
patients with relapsed non-Hodgkin lymphoma (NHL). Whether
or not the addition of rituximab to either preparative regimen
(R-BEAM or R-BEAC) provides a benefit when given prior to
ASCT is unclear.
In an attempt to compare the efficacy, outcome, and toxicity of
BEAM (with or without rituximab) (n 5 36) and BEAC (with or
without rituximab) (n 5 21) in patients with NHL undergoing
ASCT, we retrospectively evaluated our center’s experience between
January 2007 and April 2010.
Out of 57 patients with relapsedNHL (median age 56 y; range 25-
72 y), 13 patients received BEAM (n 5 6) or BEAC (n 5 7) and 44
patients received R-BEAM (n 5 29) or R-BEAC (n 5 15) prior to
ASCT. All patients received rituximab containing salvage chemo-
therapy prior to transplantation.
The probability of disease-free survival (DFS) (80% in BEAM/
BEAC versus 70% in R-BEAM/R-BEAC group; p 5 0.69) and
overall survival (OS) (68% in BEAM/BEAC versus 80% in R-
BEAM/R-BEAC group; p 5 0.31) were comparable in both the
groups at 2 years. The probability of DFS (100% in BEAC ver-
sus 70% in R-BEAC group; p 5 0.55; and 71% in BEAM and
69% in R-BEAM group; p 5 0.47) and OS (100% in BEAC ver-
sus 92% in R-BEAC group; p 5 0.54; and 60% in BEAM and
80% in R-BEAM group; p 5 0.22) were also comparable at 2
years.
There was no difference in engraftment kinetics, grade III-IV tox-
icities, and average length of stay among the different groups.
In conclusion, the addition of rituximab to either preparative reg-
imen did not add any benefit to our patients undergoing ASCT for
B-cell NHL. It is possible that the universal use of rituximab with
prior salvage therapies might have abrogated the benefit of R-
BEAM/R-BEAC over BEAM/BEAC in this study. Whether or not
the addition of rituximab to the preparative regimens prior to
ASCT in patients with NHL truly adds any benefit needs to be stud-
ied in a larger prospective trial.549
APREPITANT: TREATMENT IN HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) PATIENTS REFRACTORY TO FIRST AND SECOND
LINE ANTIEMETICS
Booth, D. Alfred Hospital, Melbourne, Victoria, Australia
Chemotherapy induced nausea and vomiting (CINV) is a distressing
side effect of the transplant procedure.Evidencebasedguidelines exist to
direct antiemetic prescribing for the prevention ofCINV.There ismin-
imal research providing guidance in the management patients with de-
layed emesis despite appropriate preventative strategies for CINV,
particularly afterHSCT. Aprepitant is a neurokinin-1 antagonist, which
incombinationwith5HT3antagonists anddexamethasone is effective inpreventingacuteanddelayedemesis afterhighlyemetogenicchemother-
apy. Aprepitant has been utilised in HSCT for prevention of CINV.
Aim:To assess the efficacy of aprepitant for the treatment of refrac-
tory emesis following HSCT.
Methods: Patients transplanted between Sept 2008 to Aug 2009,
experiencing more than one emetic episode or persistent nausea
score . 5/10 for more than 24 hours after review of antiemetic
therapy were included. Aprepitant was administered in addition
to current antiemetic therapy, as either 115mg IV daily or
125mg po stat and then 80 mg daily. The number of vomiting ep-
isodes, dry retches, nausea score on a ten point scale and break-
through antiemetic use was recorded at baseline and daily until
aprepitant ceased. A complete response was defined as no emetic
episodes, nausea score of 0/10 and no breakthrough antiemetic
use. Major response was defined as no emetic episodes with reduc-
tion of nausea score from baseline of at least 50% and partial
response as no emetic episodes but reduction in nausea score of
\ 50%.
Results: During the audit period 14 patients were prescribed apre-
pitant to treat emesis. A complete response was seen in 4/14
(28%), major response in 2/14 (14%) and partial response in 4/14
(28%) with an overall repose rate of 10/14 (71%). Responses were
sustained.
Conclusion: The addition of aprepitant can prevent emesis and
reduce nausea score in HSCT patients refractory to first and second
line antiemetic therapy.550
WHAT GOES UP MUST COME DOWN: VORICONAZOLE AND CYCLO-
SPORIN IN A PAEDIATRIC CORD AND MARROW TRANSPLANT UNIT
Wright, F.A.1,2, Daly, G.E.1,2, Song, E.Y.3,4, O’Brien, T.A.1,3,4 1Sydney
Children’s Hospital, Randwick, NSW, Australia; 2Sydney Children’s Hos-
pital, Randwick, NSW, Australia; 3Sydney Cord and Marrow Transplant
Program, Randwick, NSW, Australia; 4University of New South Wales,
Randwick, NSW, Australia
Voriconazole’s addition to the antifungal armamentarium has
been revolutionary. Its use in invasive fungal infection is of particular
utility in haematopoietic stem cell transplant (HSCT). Voriconazole
inhibits hepatic enzymes placing HSCT patients at risk of drug in-
teractions and toxicity from calcineurin inhibitors. Limited safety
and efficacy data exist for pediatric HSCT warranting investigation.
Objective: To investigate the safety and efficacy of voriconazole in
a pediatric HSCT unit 2008-10.
Method: A retrospective chart review of 43 consecutive allogeneic
transplants identified patients who received voriconazole from con-
ditioning until Day 100.
Results: 39 out of 43 (90.7%) patients are alive with a median follow
up of 17 months (1-32). There were no deaths from fungal infection.
42 of 43 patients received fungal prophylaxis. 35 patients were clas-
sified as low risk of infection and received fluconazole. 7 patients
were high risk due to pre transplant infection and received voricona-
zole. 1 patient on voriconazole developed mucormycosis and was ef-
fectively treated with posaconazole. 2 patients had suspected fungal
disease and had treatment with another agent. 4 patients continued
on prophylaxis with no demonstration of fungal disease. 13 of 43
(30.2%) fluconazole prophylaxis patients changed to voriconazole
treatment for suspected fungal infection with symptom resolution
in all patients.
Voriconazole was well tolerated. 1 patient withdrew due to toxic-
ity (confusion, rash). Hepatic dysfunction (GGT 2x normal) was sig-
nificantly higher in the voriconazole group (p\0.01). There was no
difference in transaminitis across the two groups.
On voriconazole initiation, cyclosporin dose was modified on
a risk adjusted basis. Cyclosporin level, creatinine, nephrotoxic
agents and GVHD were used to inform decision. There was no dif-
ference in cyclosporin levels or renal impairment (2 x baseline CR
urea) in the voriconazole group compared to those who received
other agents.
Conclusion: Safety and efficacy data are limited for new antifungals
when used with standard medications in pediatric HSCT. This small
series demonstrated voriconazole has acceptable toxicity and can be
prescribed without increasing cyclosporin toxicity. Currently, a dos-
ing algorithm is under evaluation to determine cyclosporin dose
